Podcast

Improving the Application of Shared Decision-Making in the Selection of SLE Treatments

Launch Date
01/11/2021
Credit Amount
0.00 Expired
Credit Expires
02/11/2022
This activity is part of a series

Faculty

Allan Gibofsky, MD, JD, MACR, FACP, FCLM
Professor of Medicine, Weill Cornell Medicine
Attending Rheumatologist and Co-Director, Clinic for Inflammatory Arthritis, Hospital for Special Surgery, New York, NY
Allan Gibofsky, MD, JD, MACR, FACP, FCLM

Allan Gibofsky, MD, JD, MACR, FACP, FCLM, serves as Professor of Medicine in the Department of Healthcare Policy and Research at Weill Cornell Medicine. Dr Gibofsky is an attending physician and rheumatologist at the Hospital for Special Surgery, where he is Co- Director of the Clinic for Inflammatory Arthritis. He received his undergraduate degree from Brooklyn College of the City University of New York, his medical degree from Weill Medical College of Cornell University, and his law degree from Fordham University School of Law. He did his internship in pathology, followed by a residency in medicine at New York Hospital. He completed a fellowship in rheumatology/immunology jointly at Hospital for Special Surgery and at The Rockefeller University. Dr Gibofsky has authored or co-authored numerous papers and textbook chapters, primarily on rheumatic diseases and legal aspects of medical practice. He is known for his work on mechanisms of host-microbe interactions in rheumatology, and, in particular, for his basic and clinical studies on rheumatic fever.

Currently Secretary-Treasurer of The New York Rheumatism Association, Dr Gibofsky is past Chair of the Medical & Scientific Committee of the New York Chapter of The Arthritis Foundation and is a recipient of its Physicians’ Leadership Award. He also served as a member of the local and national Arthritis Foundation Board of Trustees and was Chair for Professional Education. Dr Gibofsky has participated in numerous professional and public education programs, nationally and internationally. He served as President of The American College of Rheumatology and was recently named a Master. Dr Gibofsky is a Jonas Salk Scholar of the City University and an Alumnus of the Year of Brooklyn College. He is past President of the American College of Legal Medicine and is past Chair of the American Board of Legal Medicine. Dr Gibofsky is past Chair of the Arthritis Advisory Committee of the Food and Drug Administration and continues as a special consultant to that committee.

Richard A. Furie, MD
Professor of Medicine, Zucker School of Medicine at Hofstra/Northwell
Chief, Division of Rheumatology, Northwell Health Great Neck, NY
Richard A. Furie, MD

Dr. Richard Furie, Chief of the Division of Rheumatology at Northwell Health, is a rheumatologist whose activities for the last several decades have focused on patient care, physician education, and clinical research in the area of anti-rheumatic drug development. He directs The Program in Novel Therapeutics, the Health System’s clinical research program in musculoskeletal disease. He also directs the Hospital?s SLE and Autoimmune Disease Treatment Center, which has become internationally recognized for its role in the development of new therapies for SLE. Regarded as one of the senior rheumatologists in the New York metropolitan area, Dr. Furie has served as a volunteer for the local chapters of the Arthritis Foundation and the Lupus Alliance, the Lupus Foundation of America, the SLE Foundation, the Lupus Research Alliance, and Lupus Therapeutics. For 20 years he served on many committees of the American College of Rheumatology and was named a Master of the College in 2018. Although often featured as a speaker at national and international conferences, Dr. Furie’s favorite educational venue is at home with his colleagues and trainees.

Explore By Section
Statement of Need Learning Objectives Financial Support Target Audience Credit Information Disclosure Declaration Obtaining Credits

Statement of Need

Patient-reported outcomes (PROs) provide insight into patients’ experiences related to their illness, values, preferences, and goals of care and may therefore be useful as predictors of increased risk of mortality in patients with systemic lupus erythematosus (SLE). Due to their ease of use, PROs can be measured easily, quickly, and reliably, especially in communities where access to rheumatologists may be limited. As patients, and their families, prefer to be engaged in their care, it is imperative that clinicians focus on including personalized decision-making, educating patients about their disease and treatment options, and updating them on the progress of their care. However, there continue to be barriers to shared decision-making (SDM) in SLE, including medication risk aversion, prognosis uncertainty, and the financial and administration burdens associated with SLE care.

The final episode in this CMEOCast podcast series on SLE addresses the impact and burden of SLE on quality of life, the integration of PROs when caring for patients with SLE, and the implementation of best practices for SDM in order to engage patients as partners in their care.

Learning Objectives

At the end of this CME/CE activity, participants should be able to: incorporate SDM into the selection of safe and effective SLE treatments to improve disease outcomes.

The following learning objectives pertain only to those requesting CNE or CPE credit: Describe ways SDM can be incorporated into the selection of safe and effective SLE treatments to improve disease outcomes.

Financial Support

Supported by an educational grant from AstraZeneca Pharmaceuticals.

Target Audience

Rheumatologists, dermatologists, primary care physicians, PAs, nurse practitioners, nurses, and pharmacists.

Credit Information

Physicians (ACCME) 1.0

CME Outfitters, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists/Pharmacy Tech (ACPE) 1.0

This application-based activity is approved for 1.0 contact hour (0.10 CEUs) of continuing pharmacy credit.
Activity UAN: JA0007185-0000-21-095-H01-P

ABIM MOC 1.0

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Note to Nurse Practitioners

Nurse Practitioners can apply for AMA PRA Category 1 Credit ™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit ™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Gibofsky reports that he is on the advisory committee for AbbVie Inc.; Aurinia Pharmaceuticals Inc.; Eli Lilly and Company; Gilead Sciences, Inc.; Novartis; Pfizer Inc.; and Samumed. He is a consultant for AbbVie Inc.; Acquist Therapeutics, Inc.; Amgen Inc.; Eli Lilly and Company; Gilead Sciences, Inc.; Novartis; Pfizer Inc.; and Samumed. He is a stock shareholder (directly purchased) for AbbVie Inc.; Johnson & Johnson; Pfizer Inc.; and Regeneron Pharmaceuticals, Inc.

Dr. Furie reports that he receives research support from Amgen Inc.; AstraZeneca/Medimmune; Biogen Idec; Boehringer-Ingelheim; Bristol-Myers Squibb Company; Eli Lilly and Company; Genentech, Inc./Roche; GlaxoSmithKline; Kezar Life Sciences, Inc.; Nektar Therapeutics; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc. He is a consultant for Alexion Pharmaceuticals, Inc.; AstraZeneca/Medimmune; Biogen Idec; Boehringer-Ingelheim; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Eli Lilly and Company; EMD Serono, Inc.; Equillium, Inc.; Galapagos; Genentech, Inc./Roche; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Kezar Life Sciences, Inc.; MorphoSys US Inc.; Novartis; Reistone Biopharma; Sanofi; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc. He is an investigator for Amgen Inc.; AstraZeneca/Medimmune; Biogen Idec; Boehringer-Ingelheim; Bristol-Myers Squibb Company; Eli Lilly and Company; EMD Serono, Inc.; Equillium, Inc.; Genentech, Inc./Roche; GlaxoSmithKline; Kezar Life Sciences, Inc.; Nektar Therapeutics; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc. He is a committee member for the Lupus Research Alliance and The Lupus Academy.

Disclosures were obtained from the CME Outfitters, LLC, staff: No disclosures to report.

  • Jeffrey Helfand, DO (peer reviewer) has no disclosures to report.
  • Mae Ochoa, RPh (peer reviewer) has no disclosures to report.
  • Susan Perry (planning committee) has no disclosures to report.
  • Jan Perez (planning committee) has no disclosures to report.
  • Sharon Tordoff (planning committee) has no disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Obtaining Credits

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

NOTE: Pharmacist CE Universal Activity Number, Enduring: JA0007185-0000-21-095-H01-P

Questions about this activity?

Call us at (877) CME-PROS or (877) 263-7767.

PD-049-021121-13

Improving the Application of Shared Decision-Making in the Selection of SLE Treatments
Event Date: 01/11/2021

Activities in the Series

02/11/2021

Safety and Efficacy of Emerging Treatments in the Management of Systemic Lupus Erythematosus (SLE)

0.00 Expired
Learn More